News


Life Science | 2018-01-08
Kuros Biosciences Expands License Agreement with Checkmate

Schlieren (Zurich), Switzerland, January 8, 2018 – Kuros Biosciences (SIX: KURN) announced today that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) access to Kuros’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis.

 

The amendment extends the field from oncology to all indications and broadens the range of product candidates covered. In exchange for the amendment of the license, Kuros receives an upfront payment

 

“We are excited about the amendment of the existing agreement with Checkmate and continue to believe that Checkmate is well positioned to advance treatment options for patients”, commented Joost de Bruijn, CEO of Kuros. “The Checkmate team is pleased to obtain these rights to Kuros’ VLP platform, which we believe has a great deal of potential for further clinical development”, affirmed Art Krieg, CEO of Checkmate.

 

For further information, please contact:

Joost de Bruijn

Chief Executive Officer

Tel +31 6 21 21 76 03

Joost.de.bruijn@kurosbio.com

 

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline

 

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

 


Last News

2018-01-08
Kuros Biosciences Expands License Agreement with Checkmate
 
Legal informationrealisation digitalcube